Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments

DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought down from $80. The firm anticipated that intensifying competition within Dexcom’s primary insulin-intensive segments throughout 2026 and 2027 would limit the stock’s valuation multiple and hinder its performance in the near-to-medium term.

On January 9, Bernstein adjusted its outlook for DexCom, increasing the price target to $86 from $84 while maintaining an Outperform rating. This update came as US healthcare stocks showed signs of recovery following a significant low point in September 2025. The firm noted that as the macroeconomic and policy uncertainties that hampered the sector throughout 2025 begin to clear, healthcare equities are well-positioned for a stronger performance in 2026.

Furthermore, on January 7, RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on DexCom Inc. (NASDAQ:DXCM) while setting a price target of $85.

DexCom Inc. (NASDAQ:DXCM) is a medical device company that focuses on the design, development, and commercialization of CGM (continuous glucose monitoring) systems in the US and internationally.

While we acknowledge the potential of DXCM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.